93353-66-3 Usage
Methyl ester derivative
6-bromo-1-naphthoic acid The compound is derived from 6-bromo-1-naphthoic acid by replacing the carboxyl group (-COOH) with a methyl ester group (-COOCH3).
Class
Naphthalene carboxylic acids The compound belongs to the class of naphthalene carboxylic acids, which are organic compounds containing a naphthalene ring structure and a carboxylic acid group.
Appearance
Yellow to brown solid The compound has a yellow to brown color in its solid form.
Molecular weight
279.118 g/mol The molecular weight of the compound is 279.118 grams per mole, indicating the mass of a single molecule.
Uses
Organic synthesis, pharmaceuticals, agrochemicals, and dyes The compound is commonly used in various organic synthesis reactions and as an intermediate in the production of pharmaceuticals, agrochemicals, and dyes.
Potential applications
Materials science and organic electronic devices Due to its unique chemical properties and structural features, the compound has potential applications in the field of materials science and organic electronic devices.
Check Digit Verification of cas no
The CAS Registry Mumber 93353-66-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,3,5 and 3 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 93353-66:
(7*9)+(6*3)+(5*3)+(4*5)+(3*3)+(2*6)+(1*6)=143
143 % 10 = 3
So 93353-66-3 is a valid CAS Registry Number.
93353-66-3Relevant articles and documents
A new approach to rapid parallel development of four neurokinin antagonists. Part 2. Synthesis of ZD6021 cyano acid
Moseley, Jonathan D.,Moss, William O.,Welham, Matthew J.,Ancell, Claire L.,Banister, John,Bowden, Sharon A.,Norton, Glenn,Young, Maureen J.
, p. 58 - 66 (2003)
The manufacture of ZD6021 cyano acid (1) using a new project approach is described. Research Department processes were scaled up to 100 L if process safety anal robustness were not compromised; other factors were treated according to the new approach. By using this strategy, we were able to manufacture a key intermediate on sufficient scale to support delivery of 1 kg quantities of bulk drug within 6 months of the start of lab work.
